Vera Therapeutics

VERAPhase 3

South San Francisco, United StatesFounded 2016veratx.com

Vera Therapeutics is advancing a pipeline of immunology-focused therapies, with its lead program, atacicept, showing promise in IgA nephropathy, a progressive kidney disease with high unmet need. The company's strategy centers on targeting B-cell and plasma cell pathways to address autoimmune conditions. With a Phase 2b/3 trial (ORIGIN) ongoing for atacicept in IgAN, Vera is positioned as a key player in the nephrology and immunology space, backed by experienced leadership and public market funding.

Market Cap

$2.9B

Founded

2016

Employees

50-100

Focus

Biotech

VERA · Stock Price

USD 40.53+17.81 (+78.39%)

Historical price data

AI Company Overview

Technology Platform

Focused on modulating B-cell and plasma cell biology through targeted fusion proteins and antibodies to treat autoimmune diseases.

Pipeline Snapshot

6 drugs in pipeline, 2 in Phase 3

Drug	Indication	Stage
Atacicept + Placebo	Lupus Nephritis (LN)	Phase 3
Atacicept	IgA Nephropathy	Phase 3
Atacicept 150 mg	IgA Nephropathy (IgAN)	Phase 2
MAU868	BK Virus Infection	Phase 2
Atacicept	pMN	Phase 2

Opportunities

The primary growth opportunity is the successful development and commercialization of atacicept for IgA nephropathy, a large market with high unmet need.

Expansion into lupus nephritis and other B-cell mediated autoimmune diseases represents significant additional pipeline value.

Positive clinical data could also attract strategic partnership or acquisition interest.

Risk Factors

Key risks include clinical trial failure of the lead candidate atacicept, intense and growing competition in the IgAN space, regulatory hurdles, and the need for future capital raises before achieving profitability.

The company's value is highly concentrated in a single clinical asset.

Competitive Landscape

Vera faces competition from Calliditas, Travere, Novartis, Otsuka, and others in the evolving IgAN market. Its differentiation hinges on atacicept's dual inhibition of APRIL and BAFF, potentially offering superior efficacy in reducing pathogenic IgA1, and its subcutaneous administration route.

Publications

Patents

Pipeline